-
1
-
-
34250679750
-
Epidemiology of hepatitis C virus infection
-
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436-41.
-
(2007)
World J Gastroenterol
, vol.13
, pp. 2436-2441
-
-
Alter, M.J.1
-
2
-
-
0027243462
-
Risk factors for hepatocellular carcinoma among patients with chronic liver disease
-
Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-801.
-
(1993)
N Engl J Med
, vol.328
, pp. 1797-1801
-
-
Tsukuma, H.1
Hiyama, T.2
Tanaka, S.3
Nakao, M.4
Yabuuchi, T.5
Kitamura, T.6
Nakanishi, K.7
Fujimoto, I.8
Inoue, A.9
Yamazaki, H.10
Kawashimaet, T.11
-
3
-
-
78649447077
-
Hepatitis C and hepatocellular carcinoma
-
Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol. 2010;9(Suppl):119-22.
-
(2010)
Ann Hepatol
, vol.9
, pp. 119-122
-
-
Fassio, E.1
-
4
-
-
0025887360
-
Hepatocellular carcinoma in Italian patients with cirrhosis
-
Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675-80.
-
(1991)
N Engl J Med
, vol.325
, pp. 675-680
-
-
Colombo, M.1
Franchis, R.2
Ninno, E.3
Sangiovanni, A.4
Fazio, C.5
Tommasini, M.6
Donato, M.F.7
Piva, A.8
Carlo, V.9
Dioguardi, N.10
-
5
-
-
0031041924
-
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients
-
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-72.
-
(1997)
Gastroenterology
, vol.112
, pp. 463-472
-
-
Fattovich, G.1
Giustina, G.2
Degos, F.3
Tremolada, F.4
Diodati, G.5
Almasio, P.6
Nevens, F.7
Solinas, A.8
Mura, D.9
Brouwer, J.T.10
Thomas, H.11
Njapoum, C.12
Casarin, C.13
Bonetti, P.14
Fuschi, P.15
Basho, J.16
Tocco, A.17
Bhalla, A.18
Galassini, R.19
Noventa, F.20
Schalm, S.W.21
Realdi, G.22
more..
-
6
-
-
33947360829
-
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
-
Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-87.
-
(2007)
Hepatology
, vol.45
, pp. 579-587
-
-
Bruno, S.1
Stroffolini, T.2
Colombo, M.3
Bollani, S.4
Benvegnu, L.5
Mazzella, G.6
Ascione, A.7
Santantonio, T.8
Piccinino, F.9
Andreone, P.10
Mangia, A.11
Gaeta, G.B.12
Persico, M.13
Fagiuoli, S.14
Almasio, P.L.15
-
7
-
-
19944428400
-
Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival
-
Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105-14.
-
(2005)
Ann Intern Med
, vol.142
, pp. 105-114
-
-
Shiratori, Y.1
Ito, Y.2
Yokosuka, O.3
Imazeki, F.4
Nakata, R.5
Tanaka, N.6
Arakawa, Y.7
Hashimoto, E.8
Hirota, K.9
Yoshida, H.10
Ohashi, Y.11
Omata, M.12
-
8
-
-
33745838657
-
Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis
-
Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409-14.
-
(2006)
J Viral Hepat
, vol.13
, pp. 409-414
-
-
Hung, C.H.1
Lee, C.M.2
Lu, S.N.3
Wang, J.H.4
Hu, T.H.5
Tung, H.D.6
Chen, C.H.7
Chen, W.J.8
Changchien, C.S.9
-
9
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-84.
-
(2007)
Ann Intern Med
, vol.147
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
Reichen, J.4
Hofmann, W.P.5
Zeuzem, S.6
Manns, M.P.7
Hansen, B.E.8
Schalm, S.W.9
Janssen, H.L.10
-
10
-
-
54749091723
-
Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis
-
Floreani A, Baldo V, Rizzotto ER, Carderi I, Baldovin T, Minola E. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis. J Clin Gastroenterol. 2008;42:734-7.
-
(2008)
J Clin Gastroenterol
, vol.42
, pp. 734-737
-
-
Floreani, A.1
Baldo, V.2
Rizzotto, E.R.3
Carderi, I.4
Baldovin, T.5
Minola, E.6
-
11
-
-
77952704228
-
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study
-
Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51:2069-76.
-
(2010)
Hepatology
, vol.51
, pp. 2069-2076
-
-
Bruno, S.1
Crosignani, A.2
Facciotto, C.3
Rossi, S.4
Roffi, L.5
Redaelli, A.6
Franchis, R.7
Almasio, P.L.8
Maisonneuve, P.9
-
12
-
-
77951652616
-
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
-
Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652-7.
-
(2010)
J Hepatol
, vol.52
, pp. 652-657
-
-
Cardoso, A.C.1
Moucari, R.2
Figueiredo-Mendes, C.3
Ripault, M.P.4
Giuily, N.5
Castelnau, C.6
Boyer, N.7
Asselah, T.8
Martinot-Peignoux, M.9
Maylin, S.10
Carvalho-Filho, R.J.11
Valla, D.12
Bedossa, P.13
Marcellin, P.14
-
13
-
-
0036828810
-
Treatment of patients with hepatitis C and cirrhosis
-
Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002;36(5 Suppl 1):S185-94.
-
(2002)
Hepatology
, vol.36
, Issue.5
, pp. S185-S194
-
-
Wright, T.L.1
-
14
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-71.
-
(2004)
Hepatology
, vol.39
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
Seeff, L.B.4
-
15
-
-
33751009135
-
Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b
-
Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat. 2006;13:811-20.
-
(2006)
J Viral Hepat
, vol.13
, pp. 811-820
-
-
Abergel, A.1
Hezode, C.2
Leroy, V.3
Barange, K.4
Bronowicki, J.P.5
Tran, A.6
Alric, L.7
Castera, L.8
Bernard, P.H.9
Henquell, C.10
Lafeuille, H.11
Ughetto, S.12
Darcha, C.13
Chevallier, M.14
Martineau, N.15
Dubost, S.16
Randl, K.17
Dhumeaux, D.18
Bommelaer, G.19
Bonny, C.20
more..
-
16
-
-
33750078958
-
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin
-
Helbling B, Jochum W, Stamenic I, Knopfli M, Cerny A, Borovicka J, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat. 2006;13:762-9.
-
(2006)
J Viral Hepat
, vol.13
, pp. 762-769
-
-
Helbling, B.1
Jochum, W.2
Stamenic, I.3
Knopfli, M.4
Cerny, A.5
Borovicka, J.6
Gonvers, J.J.7
Wilhelmi, M.8
Dinges, S.9
Müllhaupt, B.10
Esteban, A.11
Meyer-Wyss, B.12
Renner, E.L.13
-
17
-
-
77956268664
-
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing
-
Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010;53:616-23.
-
(2010)
J Hepatol
, vol.53
, pp. 616-623
-
-
Cheng, W.S.1
Roberts, S.K.2
McCaughan, G.3
Sievert, W.4
Weltman, M.5
Crawford, D.6
Rawlinson, W.7
Marks, P.S.8
Thommes, J.9
Rizkalla, B.10
Yoshihara, M.11
Dore, G.J.12
-
18
-
-
0036788338
-
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
-
McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-9.
-
(2002)
Gastroenterology
, vol.123
, pp. 1061-1069
-
-
McHutchison, J.G.1
Manns, M.2
Patel, K.3
Poynard, T.4
Lindsay, K.L.5
Trepo, C.6
Dienstag, J.7
Lee, W.M.8
Mak, C.9
Garaud, J.J.10
Albrecht, J.K.11
-
19
-
-
79951679619
-
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
-
Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011;54:415-21.
-
(2011)
J Hepatol
, vol.54
, pp. 415-421
-
-
Sarrazin, C.1
Susser, S.2
Doehring, A.3
Lange, C.M.4
Muller, T.5
Schlecker, C.6
Herrmann, E.7
Lötsch, J.8
Berg, T.9
-
20
-
-
84890913301
-
Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients
-
Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol. 2013;19:8924-8.
-
(2013)
World J Gastroenterol
, vol.19
, pp. 8924-8928
-
-
Mangia, A.1
Mottola, L.2
Santoro, R.3
-
21
-
-
84862553194
-
Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients
-
Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther. 2012;36:104-14.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 104-114
-
-
Rangnekar, A.S.1
Fontana, R.J.2
-
22
-
-
79953298817
-
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection
-
Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One. 2011;6:e18322.
-
(2011)
PLoS One
, vol.6
, pp. e18322
-
-
Lin, C.Y.1
Chen, J.Y.2
Lin, T.N.3
Jeng, W.J.4
Huang, C.H.5
Huang, C.W.6
Chang, S.W.7
Sheen, I.S.8
-
23
-
-
84866156904
-
Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro
-
Ramos JA, Silva R, Hoffmann L, Ramos AL, Cabello PH, Urmenyi TP, et al. Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Res Notes. 2012;5:508.
-
(2012)
BMC Res Notes
, vol.5
, pp. 508
-
-
Ramos, J.A.1
Silva, R.2
Hoffmann, L.3
Ramos, A.L.4
Cabello, P.H.5
Urmenyi, T.P.6
Villella-Nogueira, C.A.7
Lewis-Ximenez, L.8
Rondinelli, E.9
-
24
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales, F.L.6
Häussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Lin, A.12
Hoffman, J.13
Yu, J.14
-
25
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.9
Albrecht, J.K.10
-
26
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette, H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
Ramadori, G.7
Bodenheimer, H.8
Bernstein, D.9
Rizzetto, M.10
Zeuzem, S.11
Pockros, P.J.12
Lin, A.13
Ackrill, A.M.14
-
27
-
-
49949115600
-
Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis
-
Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther. 2008;13:663-73.
-
(2008)
Antivir Ther
, vol.13
, pp. 663-673
-
-
Roffi, L.1
Colloredo, G.2
Pioltelli, P.3
Bellati, G.4
Pozzpi, M.5
Parravicini, P.6
Bellia, V.7
Poggio, P.8
Fornaciari, G.9
Ceriani, R.10
Ramella, G.11
Corradi, C.12
Rossini, A.13
Bruno, S.14
-
28
-
-
4344578833
-
Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial
-
Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol. 2004;41:474-81.
-
(2004)
J Hepatol
, vol.41
, pp. 474-481
-
-
Bruno, S.1
Camma, C.2
Marco, V.3
Rumi, M.4
Vinci, M.5
Camozzi, M.6
Rebucci, C.7
Bona, D.8
Colombo, M.9
Craxì, A.10
Mondelli, M.U.11
Pinzello, G.12
-
29
-
-
33645998724
-
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan
-
Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int. 2006;26:73-81.
-
(2006)
Liver Int
, vol.26
, pp. 73-81
-
-
Yu, M.L.1
Dai, C.Y.2
Lin, Z.Y.3
Lee, L.P.4
Hou, N.J.5
Hsieh, M.Y.6
Chen, S.C.7
Hsieh, M.Y.8
Wang, L.Y.9
Chang, W.Y.10
Chuang, W.L.11
-
30
-
-
79951675730
-
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
-
Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol. 2011;54:408-14.
-
(2011)
J Hepatol
, vol.54
, pp. 408-414
-
-
Kawaoka, T.1
Hayes, C.N.2
Ohishi, W.3
Ochi, H.4
Maekawa, T.5
Abe, H.6
Tsuge, M.7
Mitsui, F.8
Hiraga, N.9
Imamura, M.10
Takahashi, S.11
Kubo, M.12
Tsunoda, T.13
Nakamura, Y.14
Kumada, H.15
Chayama, K.16
-
31
-
-
84907875950
-
Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan
-
Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J, et al. Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan. Hepatol Res. 2014;44:983-92.
-
(2014)
Hepatol Res
, vol.44
, pp. 983-992
-
-
Shakado, S.1
Sakisaka, S.2
Okanoue, T.3
Chayama, K.4
Izumi, N.5
Toyoda, J.6
Tanaka, E.7
Ido, A.8
Takehara, T.9
Yoshioka, K.10
Hiasa, Y.11
Nomura, H.12
Seike, M.13
Ueno, Y.14
Kumada, H.15
-
32
-
-
33750987680
-
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
-
Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62:699-709.
-
(2006)
Br J Clin Pharmacol
, vol.62
, pp. 699-709
-
-
Snoeck, E.1
Wade, J.R.2
Duff, F.3
Lamb, M.4
Jorga, K.5
-
33
-
-
11144316875
-
Hematologic side effects of interferon and ribavirin therapy
-
Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol. 2005;39(1 Suppl):S3-8.
-
(2005)
J Clin Gastroenterol
, vol.39
, Issue.1
, pp. S3-S8
-
-
Kowdley, K.V.1
-
34
-
-
84859583276
-
Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-alpha
-
Hu CC, Weng CH, Lin CL, Tien HC, Kuo YL, Chien CH, et al. Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-alpha. Ren Fail. 2012;34:429-34.
-
(2012)
Ren Fail
, vol.34
, pp. 429-434
-
-
Hu, C.C.1
Weng, C.H.2
Lin, C.L.3
Tien, H.C.4
Kuo, Y.L.5
Chien, C.H.6
Yen, C.L.7
Lin, C.Y.8
Chien, R.N.9
-
35
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis C infection
-
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87.
-
(2013)
N Engl J Med
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
Rodriguez-Torres, M.4
Hassanein, T.5
Gordon, S.C.6
Schultz, M.7
Davis, M.N.8
Kayali, Z.9
Reddy, K.R.10
Jacobson, I.M.11
Kowdley, K.V.12
Nyberg, L.13
Subramanian, G.M.14
Hyland, R.H.15
Arterburn, S.16
Jiang, D.17
McNally, J.18
Brainard, D.19
Symonds, W.T.20
McHutchison, J.G.21
Sheikh, A.M.22
Younossi, Z.23
Gane, E.J.24
more..
-
36
-
-
84877739274
-
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
-
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-77.
-
(2013)
N Engl J Med
, vol.368
, pp. 1867-1877
-
-
Jacobson, I.M.1
Gordon, S.C.2
Kowdley, K.V.3
Yoshida, E.M.4
Rodriguez-Torres, M.5
Sulkowski, M.S.6
Shiffman, M.L.7
Lawitz, E.8
Everson, G.9
Bennett, M.10
Schiff, E.11
Al-Assi, M.T.12
Subramanian, G.M.13
An, D.14
Lin, M.15
McNally, J.16
Brainard, D.17
Symonds, W.T.18
McHutchison, J.G.19
Patel, K.20
Feld, J.21
Pianko, S.22
Nelson, D.R.23
more..
|